Verastem (VSTM)

[infamous]

what do you mean?

[realfast95]

since they won't need to raise any more money from dilution, the analysts don't seem to care anymore

BTIG, LLC Robert Hazlett
Cantor Fitzgerald Alethia Young
H.C. Wainwright Swayampaukula Ramakanth, Ph.D.

[infamous]

yes. one HAS to believe this will be back in the $4.00 range IMO. VSTM

[Harbor6460]

We need news. They have something in the works im sure with all that money on balance sheet niw

[infamous]

i dont understand why this isnt trading $3.50 to $6.00 IMO. this is absurd!

[realfast95]

The news we are hoping for is in combination with $GILD product
Remdesivir. Unusual options for $GILD was just cited for next week expiration $69. So maybe, perhaps wishful, the news will be sent out next week.

[elcheepo]

Of course it matters... You want to wait 20 years???

I want my gain, then I move on... I trade to win

[infamous]

does it really matter when? ill take anytime within the next 12 months which im very sure about. VSTM

[elcheepo]

when?

the paint is almost dry on the wall

[infamous]

Nothing but good news for this company. its bound to EASILY get back into the 3.20 range on air. VSTM

[infamous]

i dont think well have to wait that long. Im thinking 4.00 by Oct

[Harbor6460]

This will be 4.00 next year. A lot of cash. A lot of patents. No more sales team that did nothing. New CEO. Love this company

[realfast95]

grinding higher.

open interest 13,312 8/11 for 8/21 $2 went up by 100, last .04

Sept 28th $2 open interest 10,168 last .18

[RiskyRewards]

Looking much better

[ClayTrader]

* * $VSTM Video Chart 08-10-2020 * *

Link to Video - click here to watch the technical chart video

[RiskyRewards]

Thinking this will end nicely after two or ah, this news isn’t being ignored

[RiskyRewards]

News for a sale thats 70mil up to 311 mil, more than the current market cap, and not even up a cent

[RiskyRewards]

It’s being absorbed well right now, but agreed really weird movement after news that good

[infamous]

might be cause nasdaq is getting crushed today

[Tempy]

Sometimes it takes a few days or a week or so to get the Big Pop on good news...crazy.

[infamous]

ok im so perplexed. and this is a Nasdaq stock too. smh VSTM

[infamous]

that volume says it all. This IMO will close above 1.80 today. well see i guess.

[realfast95]

not much reaction. We need analysts to report. No earnings CC.
Perhaps Secura Bio, not being a household name.

[realfast95]

open interest for Aug 21, $2 is 13,212 last .05 (pre-market)

[infamous]

im doubling up on this if it hits 1.55 at market open. VSTM

[infamous]

i dont know about that. per chance to dream! VSTM

[infamous]

this might go ballistic this week. and we could have 50% to 150% days. who knows? this news is the best you could ask for for a cancer company!

[infamous]

i added premarket already at 1.65 and 1.60. VSTM

[Tempy]

Look at the volume already...we’re not the only ones, but I’m adding today. Anything I can under $2.00

[infamous]

theres only a few of us here right now. THIS IS TIME TO BUY IMO. we are going to be the cream of the crop. This may go to pluto. VSTM

[Tempy]

Ha ha...yep. We may see $3.00 today. Looking for a new 52 week high...

[Tempy]

Ha ha...yep! Time for New 52 week high.

[infamous]

and this is a totally undiscovered gem in the making here IMO. Great COMPANY! VSTM

[infamous]

are you kidding? try over $5.00 in a month IMO. VSTM

[Tempy]

Agree 100%...time to make a 52 week high.

[Tempy]

Looking great premarket...time to get back over $2.00.

[infamous]

thats the BEST news this company could have put out. that money will surely pave the way to higher highs on the stock chart IMO. 5.00+ here we come IMO. VSTM GREAT NEWS

[realfast95]

Verastem Oncology Signs Definitive Agreement To Sell COPIKTRA Rights To Secura Bio To Focus On Development Of VS-6766 And Defactinib In KRAS Mutant Solid Tumors; Co. Will Receive $70M Upfront Payment, Total Deal Value $311M
8:38 am ET August 10, 2020 (Benzinga) Print

Verastem Will Receive $70 Million Up-Front with Total Deal Value Up to $311 Million, Plus Double-Digit Sales Royalties

Upon Closing, Verastem's Current Programs Will Be Funded Until At Least 2024 to Develop VS-6766 and Defactinib in Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Small Cell Lung Cancer

Phase 2 Registration-Directed Trials Expected to Commence by Year End 2020 in Both Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Small Cell Lung Cancer

Enrollment in Ongoing Investigator-Initiated Phase 1/2 FRAME Study of VS-6766 and Defactinib Now Expanding to Include Pancreatic, KRAS Mutant Endometrial and KRAS-G12V Non-Small Cell Lung Cancer Cohorts

Verastem, Inc. (NASDAQ:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that it has entered into a definitive agreement to sell its global commercial and development rights to COPIKTRA (duvelisib), its marketed oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first FDA-approved dual inhibitor of PI3K-delta and PI3K-gamma, to Secura Bio, Inc., an integrated biopharmaceutical company dedicated to the worldwide commercialization of significant oncology therapies.

Verastem's sale of COPIKTRA follows the Company's previously announced strategic direction to focus on maximizing the broad potential of its RAF/MEK inhibitor (VS-6766) and FAK inhibitor (defactinib) program in KRAS mutant (KRASmt) solid tumors. Upon closing of the transaction with Secura Bio, Verastem will be dedicated to the development of this program and to deliver on clinical and regulatory milestones for the first potential indications in low-grade serous ovarian cancer (LGSOC) and KRASmt non-small cell lung cancer (NSCLC). Both LGSOC and KRASmt NSCLC are areas of high unmet patient need as there are no approved treatments and existing therapies have low response rates.

"By focusing our expertise and efforts on rapidly advancing the RAF/MEK/FAK development program, we believe we will be providing the best path forward for patients, customers, our shareholders and our company. These strategic decisions will enable us to best deliver on our mission to advance new medicines on behalf of cancer patients," said Brian Stuglik, Chief Executive Officer of Verastem Oncology. "The agreement with Secura Bio will ensure COPIKTRA continues to help more patients, leveraging the established commercial structure, support of ongoing clinical study and potential expansion into new indications."

Terms of the Definitive Sale Agreement

Verastem will receive an up-front payment of $70 million upon the closing of the transaction and is eligible to receive up to a total deal value of $311 million if certain regulatory and sales-based milestones are successfully met by Secura Bio and COPIKTRA's other rest-of-world partners, including:

A total of $45 million from two separate milestone payments for U.S. Food and Drug Administration (FDA) and European Medicines Agency approvals of COPIKTRA with label indicated for peripheral T-cell lymphoma
A total of $50 million for cumulative worldwide net sales of COPIKTRA beginning at $100 million of cumulative net sales
Verastem will receive low double-digit royalties on net sales over $100 million in U.S., Europe and the United Kingdom
Verastem will also receive 50% of licensing milestones (up to $146 million) and royalties outside of U.S., Europe and the United Kingdom

In exchange, Secura Bio will receive an exclusive worldwide license for the research, development, commercialization and manufacture of COPIKTRA in all oncology indications. Secura Bio will assume all operational and financial responsibility for activities that were previously part of Verastem's duvelisib program, including commercialization efforts in the United States and Europe, ongoing clinical trials, Verastem's partnerships with Yakult, CSPC and Sanofi and existing royalty obligations. Secura Bio and Verastem are also in discussions related to the transfer of Verastem's field sales and medical professionals.

The transaction with Secura Bio is subject to customary closing conditions and is expected to close in the third quarter of 2020.*

[infamous]

wtf is this going backwards again premarket? it was just fkn 1.73 yesterday after market

[realfast95]

based on the twitter sphere and stocktwits, Tuesday will be a kodak moment.

https://www.biorxiv.org/content/10.1101/2020.08.02.230839v1.full.pdf

VS-6766 for Covid-19 treatment. Interesting this is their other asset (not Duvelisib). "lessen the infection spread", "showed the greatest reduction in ACE2"

Remdesivir + VS-6766 combo for Covid-19 treatment. P value < 0.01

$VSTM 🚀 after hours

VS-6766 for Covid-19 treatment. Interesting this is their other asset (not Duvelisib). "lessen the infection spread", "showed the greatest reduction in ACE2"

Remdesivir + VS-6766 combo for Covid-19 treatment. P value < 0.01https://t.co/KlfsOkgn06 pic.twitter.com/3QDymUj66B

— Kevin Wolcott (@Kevin_W81) August 4, 2020

Kevin Wolcott

[TheFinalCD]

nEWS NOT ON WEBSITE YET https://investor.verastem.com/news-releases

[RiskyRewards]

Agreed August phase 2 announcement should really get the ball rolling.

[infamous]

could be. honestly this is so oversold its ridiculous. this will be at 3.50 in no time IMO. VSTM

[RiskyRewards]

Looks like reversals here

[realfast95]

open interest on Friday morning 7/31
Open interest 13,304
last .05

for Aug 21st $2 strike
when $1.34

[realfast95]

open interest on Wednesday volume

Options eod 7/29

$2 strike price for Aug 21st - last = .07
Volume 7/29 = 7,913
Open interest 7/28 = 8,849

Open interest on the morning of 7/30 is 12,533
last = .05 at 09:58

[realfast95]

Options eod 7/29

$2 strike price for Aug 21st - last = .07
Volume 7/29 = 7,913
Open interest 7/28 = 8,849

[realfast95]

July 27, 2020
8:30 am ET
Traders Circulate Clinicaltrials.gov Page Titled 'Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (DAMPEN-CI)' On Verastem/UPenn Study Sponsored By Emory
Benzinga

https://clinicaltrials.gov/ct2/show/NCT04487886?cond=COVID&sfpd_s=07%2F27%2F2020&sfpd_e=08%2F02%2F2020&sort=nwst&draw=2&rank=13

[elcheepo]

patiently waiting.

[infamous]

is there ANYONE around in this ghost town? Doesnt anyone think this stock is WAY oversold??? VSTM